Eliezer Van Allen

Has grant

Professor

Harvard University
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Dissecting the impact of noncoding structural variation in melanoma genomes

Open Date: 2021-06-01

Close Date: 2023-05-31

Articles (49)

Year:

2026

Year:

2026

Year:

2026

Categorical variants, or sets of genomic alterations constrained by shared properties, are pervasive across clinical, regulatory, and research domains in the biomedical ecosystem, yet their inconsistent and non-computable representation hinders data interoperability and clinical interpretation. We surveyed genomic knowledgebases spanning regulatory approvals and the biomedical literature and found that categorical variants underpin a substantial proportion of clinical genomics knowledge, but are largely described using incompatible bespoke models. To address this, we developed the GA4GH Categorical Variation Representation Specification (Cat-VRS), a constraint-based framework that provides a unified computable representation for both precise and intentionally broad categories across molecular and systemic variant domains. Cat-VRS enables harmonization of genomic knowledgebases, computable category-based search, and automated matching between assayed variants and categorical entities in clinical and research contexts. By providing a principled, extensible model for categorical variation, Cat-VRS enables computable reasoning over genomic variant categories and establishes a foundation for the standardized representation and exchange of genomic knowledge.

Year:

2026

New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo . Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.

Year:

2026

Year:

2025

Year:

2025

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are clinically heterogeneous malignancies whose biology and microenvironmental organization remain poorly understood. Here, we integrated single-nucleus multiomic (snRNA-seq and snATAC-seq) and spatial transcriptomic profiling across 38 well-differentiated pancreatic (pNET) and small-intestinal (siNET) tumors to define conserved malignant programs, their regulatory circuits, and spatial niches. We observed two conserved malignant cell programs spanning a continuous transcriptional spectrum: a neuronal-like program (si-cNMF1/p-cNMF1), and a secretory neuroendocrine program (si-cNMF2/p-cNMF2). Matched chromatin accessibility profiles uncovered distinct, tissue-specific regulatory networks, including MAX::MYC and MITF transcription factor binding motifs in siNETs versus ISL1 and TFAP4 in pNETs, indicating organ-specific epigenetic control. Spatial transcriptomic analyses revealed that si/p-cNMF1-high regions localized to high cell density, immune-rich tumor areas, whereas si/p-cNMF2-high regions occupied stromal and vascularized niches and co-occured with fibroblast and endothelial compartments enriched for TGFB1-ITGB1 , VEGFA-FLT1 , and LAMA2-ITGA1 signaling. Across both tumor types, the cNMF2 program was enriched in metastatic lesions and was enrichedfor pro-fibrotic and pro-angiogenic gene signatures. Thus, GEP-NETs are organized along a conserved neuronal-to-secretory axis defined by distinct epigenetic programs and spatially coupled to specific microenvironmental niches. This framework unifies NET heterogeneity across organ sites and identifies pathway-specific, microenvironment-linked vulnerabilities for therapeutic targeting.

Year:

2025

Introduction Precision oncology has informed cancer care by enabling the discovery and application of diagnostic, prognostic, and/or predictive molecular biomarkers. However, many patients lack actionable biomarkers or fail to respond to biomarker-directed therapies. Patient similarity approaches can leverage comprehensive tumor profiling and prior clinical experiences from large cohorts for decision support, facilitating broader realization of precision oncology insights. Methods We developed a deep learning-based modeling framework using real-world clinicogenomic data from a tertiary cancer center to (i) measure patient similarity based on embedded tumor genomic profiles and (ii) evaluate the association of derived patient subgroups and neighborhoods with shared therapeutic outcomes in breast cancer-specific and histology-agnostic pan-cancer settings. Results The model recovered clinically meaningful patient clusters reflecting both expected and previously unknown therapeutic associations, as well as patient-specific neighborhoods that could inform therapeutic trajectories more often than expected by chance in multiple clinical contexts. Moreover, model utility extended to patients without actionable genomic biomarkers and those with cancer of unknown primary (CUP) diagnoses, where neighborhoods aligned with independently predicted primary cancer type. These neighborhoods could also be examined over time in a continuously learning scenario. Conclusion This similarity-based modeling framework distilled complex molecular and clinical data into concise, context-specific insights that augment clinician judgment, providing a foundation for a real-time learning, patient-centered decision support model in precision oncology.

Year:

2025

Persistent stable lesions represent a common but ambiguous outcome in melanoma patients receiving immune checkpoint inhibitors (ICIs). However, these lesions are infrequently removed and poorly characterized. Here, we perform in-depth multi-omics spatial profiling on persistent stable lesions from six ICI-treated patients. In one, the proportion of viable and proliferating tumor cells was similar to that of site-matched tumors from patients progressing during ICI. Extensive infiltration with cytotoxic T cells and a high level of programmed cell death were also observed. Some quiescent cancer cells were present, but this was not the dominant tumor state. A second stable lesion, while pathologically negative, also contained proliferative tumor nests with proximate immune cells. These findings provide evidence in patients for extended tumor mass dormancy in which cell death balances ongoing proliferation and further demonstrate that persistent stable lesions can be reservoirs of viable tumor cells with implications for clinical monitoring and management. SIGNIFICANCE This study demonstrates that, following immunotherapy, persistent stable melanomas can arise through tumor mass dormancy rather than quiescence. Mass dormancy is characterized by active tumor cell proliferation and compensatory programmed cell death. Thus, viable tumor cells in some stable lesions have the potential to reactivate disease should ongoing immunosurveillance fail.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (71)

Lucia Kwak

Johns Hopkins University

UNITED STATES
View details

Filippo Birocchi

Harvard University

UNITED STATES
View details

Madeleine Torcasso

Assistant Professor

University of Chicago

UNITED STATES
View details

Roni Oren

Head of Patient Derived Xenograft (PDX) Service and Human Tissue Samples Bank

Weizmann Institute of Science

ISRAEL
View details

Ulka Vaishampayan

Professor

University of Michigan

UNITED STATES
View details

David Braun

Assistant Professor, Principal Investigator

Yale University Yale Cancer Center

UNITED STATES
View details

Andréanne Gagné

Assistant Professor

Université Laval

CANADA
View details

Olga Troyanskaya

Professor

Princeton University

UNITED STATES
View details

Francisco Martínez-Jiménez

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

Alexander Jordan

Assistant Professor

Yale University

UNITED STATES
View details

Stephanie Dougan

Associate Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Sandro Santagata

Brigham and Women's Hospital

UNITED STATES
View details

Bose Kochupurakkal

Senior Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Akash Patnaik

Deputy Chief for Translational Research

University of Chicago

UNITED STATES
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Ali Amiryousefi

University of Helsinki

FINLAND
View details

Ben Stanger

University of Pennsylvania

UNITED STATES
View details

Biren Saraiya

Assistant Professor of Medicine

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Fabian Theis

Director of the Institute of Computational Biology and Professor

Technical University of Munich

GERMANY
View details

Rahul Parikh

Associate Professor of Medicine

University of Kansas Medical Center

UNITED STATES
View details

Roxana Daneshjou

Stanford University

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Christopher Reilly

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Christine Lian

Dermatopathologist/Associate Professor

Brigham and Women's Hospital

UNITED STATES
View details

Peter Winter

Principal Investigator

Broad Institute

UNITED STATES
View details

Ryan Collins

Principal Investigator

Dana-Farber Cancer Institute

UNITED STATES
View details

Srinivas Viswanathan

Dana-Farber Cancer Institute

UNITED STATES
View details

Toni Choueiri

Director, Lank Center for Genitourinary Oncology

Dana-Farber Cancer Institute

UNITED STATES
View details

Shifra Ben-Dor

Senior Staff Scientist

Weizmann Institute of Science

ISRAEL
View details

David Kim

Assistant Professor

Stanford University

UNITED STATES
View details

Wenxin Xu

Assistant Professor of Medicine

Dana-Farber Cancer Institute

UNITED STATES
View details

Niroshana Anandasabapathy

Associate Professor of Dermatology

Weill Cornell Medical College

UNITED STATES
View details

Cheng-Zhong Zhang

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Elizabeth Buchbinder

Harvard University

UNITED STATES
View details

Abel Gonzalez-Perez

Co-PI

IRB Barcelona

SPAIN
View details

Valentina Boeva

Tenure Track Assistant Professor

ETH Zürich

SWITZERLAND
View details

Paola A. Guerrero

Research Group Leader

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Christopher J. Sweeney

University of Adelaide

AUSTRALIA
View details

Joaquin Mateo

Group Leader

Vall d´Hebron Institute of Oncology

SPAIN
View details

Giuseppe Nicolò Fanelli

University of Pisa

ITALY
View details

Franklin W. Huang

-

UNITED STATES
View details

Alex Wagner

Associate Professor

The Ohio State University College of Medicine

UNITED STATES
View details

Srivatsan Raghavan

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Eddy Saad

Dana-Farber Cancer Institute

UNITED STATES
View details

Lawrence Fong

Fred Hutch Cancer Center

UNITED STATES
View details

Filipe Carvalho

Brigham and Women's Hospital

UNITED STATES
View details

Brandon Chen

University of California, San Francisco

UNITED STATES
View details

David Yang

Dana-Farber Cancer Institute

UNITED STATES
View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Neal Lindeman

Vice Chair, Molecular Pathology and Laboratory Medicine

Weill Cornell Medicine

UNITED STATES
View details

Peter Sorger

Otto Krayer Professor of Systems Pharmacology

Harvard Medical School

UNITED STATES
View details

Alan D'Andrea

Director, Center for DNA Damage and Repair

Dana-Farber Cancer Institute

UNITED STATES
View details

Leandra Barnes

Stanford University

UNITED STATES
View details

David Liu

Assistant Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Aedin Culhane

Professor of Cancer Genomics

University of Limerick

IRELAND
View details

Yishai Levin

Lab head

Weizmann Institute of Science

ISRAEL
View details

Atish Choudhury

Dana-Farber Cancer Institute

UNITED STATES
View details

Adam Olson

Assistant Professor

UPMC Hillman Cancer Center

UNITED STATES
View details

Simona Cristea

Dana-Farber Cancer Institute

UNITED STATES
View details

Anirban Maitra

Laura and Isaac Perlmutter Professor of Pathology

NYU Langone Health

UNITED STATES
View details

Michael P. Kim

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

S. Percy Ivy

Associate Chief

National Cancer Institute

UNITED STATES
View details

Nuria Lopez-Bigas

ICREA Research Professor-Group Leader

Universitat Pompeu Fabra

SPAIN
View details

Bradley McGregor

Dana-Farber Cancer Institute

UNITED STATES
View details

Sirisha V Mukkavalli

Senior Scientist/Lab Manager

Dana-Farber Cancer Institute

UNITED STATES
View details

Rana R. McKay

University of California, San Diego

UNITED STATES
View details

Shubham Pant

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David McDermott

Beth Israel Deaconess Medical Center

UNITED STATES
View details

Alex K. Shalek

J. W. Kieckhefer Professor

Massachusetts Institute of Technology

UNITED STATES
View details

Mamta Parikh

Associate Professor

University of California Davis Comprehensive Cancer Center

UNITED STATES
View details

Jennifer Roth

Broad Institute

UNITED STATES
View details